# Clinical Trial Using the Proteolytic Fraction P1G10 From V. Cundinamarcensis to Heal Diabetic Foot Ulcer

> **NCT03700580** · PHASE2 · COMPLETED · sponsor: **Carlos E Salas** · enrollment: 50 (actual)

## Conditions studied

- Diabetic Foot
- Neuropathy, Diabetic
- Foot Ulcer

## Interventions

- **DRUG:** Hydrogel treatment
- **DRUG:** P1G10

## Key facts

- **NCT ID:** NCT03700580
- **Lead sponsor:** Carlos E Salas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-15
- **Primary completion:** 2016-10-14
- **Final completion:** 2016-10-15
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03700580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03700580, "Clinical Trial Using the Proteolytic Fraction P1G10 From V. Cundinamarcensis to Heal Diabetic Foot Ulcer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03700580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*